Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 13/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | METAP2 | P50579 | 1/20 | 0.35 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | KIF11 | P52732 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25723818 | 0.85 | SCN10A (0.39) | SCN10AKCNH2PDE10A | |
| SCHEMBL890257 | 0.77 | SCN10A (0.36) | SCN10AMETAP2DHFRSLC2A1KIF11 | |
| SCHEMBL21100918 | 0.77 | SCN10A (0.39) | SCN10AKCNH2PDE10AMETAP2KIF11 | |
| SCHEMBL25723824 | 0.77 | LMNA (0.39) | DHFRSLC2A1KIF11 | |
| SCHEMBL10147352 | 0.77 | CYP1A2 (0.37) | METAP2DHFRSLC2A1 | |
| SCHEMBL12978393 | 0.76 | DHFR (0.34) | DHFRSLC2A1 | |
| SCHEMBL25723822 | 0.76 | DYRK1A (0.46) | DHFRSLC2A1 | |
| SCHEMBL25723817 | 0.76 | DHFR (0.34) | DHFRSLC2A1 | |
| SCHEMBL20618791 | 0.73 | SCN10A (0.36) | SCN10AKCNH2PDE10AMETAP2KIF11 | |
| SCHEMBL10141921 | 0.73 | PARP1 (0.34) | DHFRSLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230030115-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO LTD (CN) | 2023-02-02 | — | — | US | disclosed |
| US-9676802-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20120039848-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120039848-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | SCN10A 4134/4885KCNH2 3887/4885PDE10A 1452/4885 |
| US-20230030115-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | ROCK1, ROCK2, RHOA | SCN10A 3860/4885KCNH2 4406/4885PDE10A 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.